WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
SJIF Impact Factor 5.990
Volume 4, Issue 11, 1921-1932. Review Article ISSN 2277– 7105

NON SMALL CELL LUNG CANCER: CLINICAL IMPLICATIONS AND FUTURE PERSPECTIVES

Pramod Singh Khatri[1]* and Babra Javaid[2]

[1]Head of Department and Program Coordinator, Dept. of Clinical Research, Amity Medical School, Amity University, Gurgaon, India.

[2]Msc Clinical Research, Amity Medical School, Amity University, Haryana

Article Received on
16 Sept. 2015,

Revised on 07 Oct. 2015,
Accepted on 28 Oct. 2015,

***Correspondence for Author**
Pramod Singh Khatri
Head of Department and Program Coordinator, Dept. of Clinical Research, Amity Medical School, Amity University, Gurgaon, India.

ABSTRACT

Recently, broad investigation has researched the reproducible molecular modifications in lung cancer, with marked accomplishment in distinguishing particular molecular cohorts of subjects. This has subsidized to a new model of classification of lung cancer. The traditional refinement between SCLC and NSCLC is no more adequate for treatment planning. Further tumor subtyping is currently needed to select best treatment regimen. Progressively, the integration of molecular testing results is a fundamental part of clinical choice making in NSCLC treatment. Molecular portrayal of lung carcinoma contributes important data regarding the subject's diagnosis, anticipation, and the potential treatment with targeted treatment. With additional proof that targeted treatment has a noteworthy improvement over customary chemotherapy when given to the eligible subjects for the assessment of epidermal growth factor receptor (EGFR) transformations and anaplastic lymphoma kinase (ALK) rearrangement are currently considered by numerous principal investigator as a standard treatment for advanced stage pulmonary adenocarcinomas. As the vision of "personalized medicine" progressively turns into an everyday reality, having a clear comprehension of the procedures involved in molecular testing of tumor samples will be paramount to the honing pathologist. There are a few promising agents for subjects with enacting EGFR mutation who experience disease recurrence of an EGFR tyrosine kinase inhibitor and have a T790M resistance transformation. Clinical trials examining adjuvant erlotinib in EGFR mutant NSCLC and contrasting erlotinib with erlotinib in addition to bevacizumab in metastatic. EGFR mutant NSCLC are continuing. Crizotinib, when

contrasted with platinum-pemetrexed, results in an unrivaled ORR and recurrence free survival in subjects with ALK rearranged NSCLC, and ceritinib is a second-line choice for such patient population, however subjects should be monitored closely for adverse events and the requirement for dose amount reduction. Necitumumab and ramucirumab exhibited an improvement in general survival in patient population with constrained alternatives. There will be a contention about the potential role of these agents since the general survival benefit seen in the stage III trials was meek. The role of prophylactic cranial irradiation and thoracic radiation treatment, two regularly utilized practices, will most likely be addressed in light of the consequences of the stage III clinical trial.

KEYWORDS:-EGFR, NSCLC, tyrosine kinase inhibitor, smoking.

INTRODUCTION

Clinically, primary lung disease is partitioned into SCLC[1-3] and NSCLC[4-7], and subjects get differential treatment in light of these criteria. NSCLC is a canopy term for various tumor types that together record for roughly 80% of lung cancers.[8-9] These incorporate the three primary subtypes of squamous-cell lung carcinoma, large cell lung carcinoma, and adenocarcinoma[10] Adenocarcinoma represents roughly 40% of all NSCLC and is more pervasive among individuals who have never smoked (figure 1). For a long time, treatment for metastatic NSCLC has utilized chemotherapy regimens for subject care with constrained impact.[11-14]



Figure 1:- Carcinoma of Lung (A) SCC. (B) SCLC. (C) ADBAC Type. (D) LCC.

Lung cancer is the most commonly analyzed malignancy on the planet. It is the main source of tumor related passing among both men and women in the India. Cigarette smoking has been appeared to be strong risk element for the consequent development of lung cancer. The prediction for all phases of lung cancer stays poor: the 5-year survival for all consolidated stage is 15%. For subjects with early stage (localized) disease, 5-year survival is altogether higher at 52%, yet mirrors the high recurrence rate of this ailment.[15-17] Subjects who present with last stage (stage IV) have a 5-year survival rate of under 5%.

Five-year survival rates for these subjects are not promising. However, for a subgroup of these subjects, there have been radical changes over last few years. Our comprehension of the basic pathology behind NSCLC at the molecular level has presented a large group of new molecularly targeted treatments, which are reforming lung cancer care. Activating (EGFR) mutation in NSCLC gave the first chance to develop molecularly characterized medicines, for example, the inhibitors gefitinib and erlotinib.[18-19] Results from latest clinical trials give plan to NSCLC subjects harboring oncogenic translocations including the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase. As hindrance of the BCR–ABL complex has changed the substance of CML analysis, oncogenic ALK fusions offer a stage forward in the diagnosis and treatment of ALK-positive NSCLC.[20]

Genetic Variations

Focused treatment is conceivably effective in selected subjects with advanced NSCLC harboring genetic changes. The 2 best portrayed instance are either ALK gene rearrangement or sensitizing EGFR transformations in their tumors.[21-22] Subjects whose tumors have EGFR exon 19 deletions or exon 21 L858R transformations are generally very sensitive to (EGFR-TKI) therapy. Subjects whose tumors have ALK gene rearrangements are typically profoundly highly to ALK inhibitors. Other noteworthy molecular variations will continue to be discovered and investigated, including BRAF changes and ROS1 and RET modifications.[23]

Sensitizing EGFR changes are found in roughly 10% of Indian subjects with NSCLC and up to half of Asian subjects; they incorporate (L858R and exon 19 deletions) Clinical characteristics connected with the vicinity of an EGFR transformation incorporate adenocarcinoma, almost no smoking history, female sex, and East Asian lineage. Some EGFR transformations are activating, yet impervious to standard EGFR TKIs, most prominently exon 20 insertion changes.[24] Most subjects treated with the first or second era

EGFR TKIs (e.g., erlotinib, gefitinib, afatinib) will develop recurrence around 1 year in the wake of initiating treatment. These subjects have developed procured resistance, connected with the determination of extra biological mutations inside of the tumor. The most widely recognized mutation is the T790M mutation, happening in 60% of subjects with EGFR transformations, as a result of the development of an exon 20 point mutation in cis region with the mutation in the EGFR.[25-27]

The vicinity of the T790M transformation in the TKI has additionally been depicted in 2 separate connections. In the first place, highly sensitive sequencing methods may have the capacity to distinguish low level clones harboring T790M that are later chosen out by EGFR-TKI therapy. As these clones may be available only in small fraction of cells, the subject may even now get clinical advantage from the initial TKI treatment, in spite of the fact that the free survival may be squatter.[28] Second, families with germline T790M have been infrequently portrayed, wherein the development of lung cancer appears to rely on the development of a second, more traditional L858R or exon 19 deletion(figure 2).

Approximately 7% of subjects with NSCLC have ALK gene rearrangements.EML4 is the most well-known fusion partner with ALK, prompting no less than 13 distinct variations, yet other fusion partner with ALK have been described. Subjects with ALK modifications have adenocarcinoma histology and zero smoking history. Most driver oncogenes have a tendency to be totally unrelated with other driver oncogenes.[29] For instance, ALK modifications have a tendency to be fundamentally unrelated with other mutations, for example, EGFR or KRAS mutations.



Figure 2:- Mutations of NSCLC

Emerging Molecular Markers

At present, EGFR change and ALK rearrangement constitute the 2 molecular alterations in NSCLC associated with targeted treatment. On the other hand, the recurrence is under half in most patient populations. In this manner, broad endeavors are ongoing to identify extra variations that can be utilized for targeted treatment.[30-31] There is at present a deficiency of molecular biomarkers with known therapeutic inferences in squamous cell carcinoma. Notwithstanding a growing list of new biomarkers that may be associated with result on targeted treatment, some current biomarkers are finding new signs in investigational treatments. In spite of the fact that list of emerging biomarkers, only a few selected instance are exhibited here.[32]

ROS1

ROS1 is another receptor tyrosine kinase in which a revamp has been recognized in NSCLC. A latest study showed location in biomarker- squamous cell carcinoma. The small molecule inhibitor Crizotinib has bustle against ROS1. Early investigation have shown a marked reaction of tumors harboring ROS1 rearrangement to Crizotinib.[33]

BRAF

Changes in BRAF have increased widespread consideration taking into account the transformation's relationship with receptiveness to targeted treatment in malignant melanoma. Around 3% of NSCLCs port a BRAF transformation. In any case, dissimilar to melanoma, BRAF changes in NSCLC are not prodigiously concentrated in a single point transformation.[34] Numerous agents are being examined in clinical trials for action in subjects with NSCLC concealing BRAF changes.

FGFR1

Amplification of FGFR1 has been recognized in a noteworthy subset of squamous cell carcinoma of the lung, and represents a standout amongst the most encouraging target in this subtype, which has generally few distinguished recurrent alterations[35] Investigations of FGFR inhibitors are right now under way and preclinical investigations of a mixed bag of inhibitors are promising.

HER2

Amplification of ERBB2 (HER2) is normally known in a subset of invasive breast carcinoma. Amplification of HER2 happens in a small rate of NSCLC. Interestingly,

transformations have additionally been distinguished in HER2 .Both amplification and transformation can bring about constitutive activation of HER2, and restraint of this molecule with various agents may demonstrate advantageous and are effectively explored.[36]

PIK3CA

Transformation in PIK3CA are seen in around 5% of squamous cell carcinomas of the lung, and various agents are under further investigation, with subjects with tumors harboring transformations getting higher precedence.[37]

KRAS

In spite of the fact that testing for KRAS transformation is variably represented taking into account the early recommendation that it serves as a negative predictor of receptiveness to targeted treatment in NSCLC, and in light of the fact that it can assume a role in algorithmic testing methodologies, developing signs propose that KRAS mutational testing may be utilized for selecting subjects for inhibitors that influence the pathway downstream of KRAS (ie, MEK inhibitor).[38]

ALK inhibitors and NSCLC: future reflection

The presence of ALK fusion oncoproteins in NSCLC was initially depicted in 2007 in two independent studies with very distinctive methodologies.[39-41] Researchers utilized tumor DNA library mutation assay to distinguish echinoderm microtubule-related protein-like 4 (EML4)–ALK, researchers have carried out one of the initial global phosphotyrosine proteomic investigations of NSCLC cell lines, recognizing various oncogenic lesions with EML4-ALK and TRK-fused gene–ALK (TFG-ALK).[42-45] Preceding the identification of ALK fusion proteins in NSCLC, the subject population who was given ALK fusions, for example, NPM–ALK in ALCL, was constrained. This number changed fundamentally with the thought of an expected 3–13% of NSCLC subjects.[46-49]

Calculated at a rate of 5% of ALK translocations, NSCLC cases are amenable to ALK-directed treatments would be anticipated to achieve 80,000 new lung tumor subjects every year around the world.[50-52] The NSCLC subject with ALK translocations are different from smoking-related lung cancer population. It is presently perceived that there is an expanding population of non-smoking-related lung cancer.[53] NSCLC subjects in which abnormalities, for example, EML4–ALK and EGFR transformations are enhanced. This population is for the most part transcendently female and tumors are frequently adenocarcinomas.[54-57]

A lot of development has been made following the beginning of ALK inhibitors, and a significant number of patent applications for ALK inhibitors have been documented, some of which have now been deciphered into reasonable options for clinical use.[58-60] The quick pace of ALK medication development is being accompanied with strong progress in diagnostics approaches to deal with NSCLC medicines. Numerous investigations and difficulties stay for the future, particularly as far as utilization of ALK inhibitors in blend with other signaling inhibitors.[61]

Closing Remarks

In this way, there are numerous signs for the abandonment of common practice from last decade offering the same treatment to all subjects with NSCLC. The pragmatic outcome of that will be a reduction in fame of the fine-needle aspiration technique for analysis. Undoubtedly, a cytological finding won't be sufficiently firm to serve as the premise for treatment guidance in the near future. It is additionally worth saying that the determination of EGFR change status is very difficult and needs an accomplished hand. The determination of subgroups of subjects with NSCLC for treatment is turning out to be progressively critical. It is similarly essential to distinguish subjects who are not liable to respond or live more as a consequence of treatment. This is particularly important for medications related with significant toxicity or for which the cost benefit proportion of the treatment is liable to be extremely high. An individualized treatment methodology is turning into an essential issue.

CONFLICTS OF INTEREST STATEMENT

The Authors declare no conflicts of interest.

REFERENCES

1. Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, DeLuca J, Ewing M, Abdulrahman R, DesRosiers C, Williams M, Fletcher J: Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 2006; 24:4833-9.
2. Wong DW, Leung EL, So KK, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer. 2009; 115:1723-1733.
3. Sasaki T, Rodig SJ, Chirieac LR, et al. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer. 2010; 46:1773-1780.

4. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007; 448:561-566.
5. Cui JJ, Tran-Dube M, Shen H, et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem. 2011; 54:6342-6363.
6. Ou SH. Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond. Drug Des Devel Ther. 2011; 5:471-485.
7. Yasuda H, de Figueiredo-Pontes LL, Kobayashi S, et al. Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1translocated lung cancer. J Thorac Oncol. 2012; 7:1086-1090.
8. Rodig SJ, Shapiro GI. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases. Curr Opin Investig Drugs. 2010; 11:1477-1490.
9. Camidge DR, Bang YJ, Kwak EL, et al. Progression free survival (PFS) from a phase I study of crizotinib (PF-02341066) in subjects with ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol. 2011; 29:a2501.
10. Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A. 2007; 104:20932-20937.
11. Turke AB, Zejnullahu K, Wu YL, et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell. 2010; 17:77-88.
12. Beau-Faller M, Ruppert AM, Voegeli AC, et al. MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naive cohort. J Thorac Oncol. 2008; 3:331-339.
13. Witt BL, Wallander ML, Layfield LJ, et al. Respiratory cytology in the era of molecular diagnostics: a review. Diagn Cytopathol. 2012; 40:556-563.
14. Rivera MP, Mehta AC. Initial diagnosis of lung cancer:ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007; 132:131S-148S.
15. Pirker R, Herth FJ, Kerr KM, et al. Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol. 2010; 5:1706-1713.
16. Ellis PM, Blais N, Soulieres D, et al. A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer. J Thorac Oncol. 2011; 6:1379-1391.

17. Timmerman R, Galvin J, Michalski J, Straube W, Ibbott G, Martin E, Abdulrahman R, Swann S, Fowler J, Choy H: RTOG 0236: stereotactic body radiation therapy to treat medically inoperable early stage lung cancer subjects. J Thorac Oncol 2009; 4(1):S299.
18. Lagerwaard FJ, Haasbeek CJ, Smit EF, Slotman BJ, Senan S: Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2008; 70:685-92.
19. Bradley J, Graham MV, Winter K, Purdy JA, Komaki R, Roa WH, Ryu JK, Bosch W, Emami B: Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using threedimensional conformal radiotherapy in subjects with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 2005; 61:318-28.
20. Lanuti M, Sharma A, Digumarthy SR, Wright CD, Donahue DM, Wain JC, Mathisen DJ, Shepard JA: Radiofrequency ablation for treatment of medically inoperable stage I non-small cell lung cancer. J Thorac Cardiovasc Surg 2009; 137:160-6.
21. Pennathur A, Abbas G, Gooding WE, Schuchert MJ, Gilbert S, Christie NA, Landreneau RJ, Luketich JD: Image-guided radiofrequency ablation of lung neoplasmin 100 consecutive subjects by a thoracic surgical service. Ann Thorac Surg 2009; 88:1601-6.
22. Dunlap NE, Biedermann GB, Yang W, Cai J, Benedict SH, Sheng K,Kavanagh BD, Larner JM: Chest wall volume receiving more than 30 Gy predicts risk of severe pain and/or rib fracture following lung SBRT. Int J Radiat Oncol Biol Phys 2008; 72:(1 Suppl 1):S36.
23. Kawase T, Takeda A, Kunieda E, Kokubo M, Kamikubo Y, Ishibashi R, Nagaoka T, Shigematsu N, Kubo A: Extrapulmonary soft-tissue fibrosis resulting from hypofractionated stereotactic body radiotherapy for pulmonary nodular lesions. Int J Radiation Oncology Biol Phys 2009; 74:349-54.
24. Nagata Y, Takayama K, Matsuo Y, Norihisa Y, Mizowaki T, Sakamoto T, Sakamoto M, Mitsumori M, Shibuya K, Araki N, Yano S, Hiraoka M: Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys 2005; 63:1427-31.
25. Cheng H, Xu X, Costa DB, et al. Molecular testing in lung cancer: the time is now. Curr Oncol Rep. 2010; 12:335-348.
26. Keedy VL, Temin S, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for subjectswith advanced non-small-cell lung cancer considering firstline EGFR tyrosine kinase inhibitor therapy. J Clin Oncol. 2011; 29:2121-2127.

27. Anderson SM. Laboratory methods for KRAS mutation analysis. Expert Rev Mol Diagn. 2011; 11:635-642.
28. Pao W, Ladanyi M. Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method. Clin Cancer Res. 2007; 13:4954-4955.
29. John T, Liu G, Tsao MS. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors. Oncogene. 2009; 28(1):S14-S23.
30. Aisner DL, Sams SB. The role of cytology specimens in molecular testing of solid tumors: techniques, limitations, and opportunities. Diagn Cytopathol. 2012; 40:511-524.
31. Jemal A, Bray F, Center MM, et al. Global cancer statistics.CA Cancer J Clin. 2011; 61:69-90.
32. Siegel R, Ward E, Brawley O, et al. Cancer statistics,2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011; 61:212-236.
33. Jemal A, Thun M, Yu XQ, et al. Changes in smoking prevalence among U.S. adults by state and region: estimates from the Tobacco Use Supplement to the Current Population Survey, 1992-2007. BMC Public Health. 2011; 11:512.
34. Subramanian J, Govindan R. Lung cancer in never smokers: a review. J Clin Oncol. 2007; 25:561-570.
35. Langer CJ, Besse B, Gualberto A, et al. The evolving role of histology in the management of advanced non-small-cell lung cancer. J Clin Oncol. 2010; 28:5311-5320.
36. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005; 97:339-346.
37. Toyooka S, Matsuo K, Shigematsu H, et al. The impact of sex and smoking status on the mutational spectrum of epidermal growth factor receptor gene in non small cell lung cancer. Clin Cancer Res. 2007; 13:5763-5768.
38. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350:2129-2139.
39. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.Science. 2004; 304:1497-1500.

40. Sartori G, Cavazza A, Sgambato A, et al. EGFR and K-ras mutations along the spectrum of pulmonary epithelial tumors of the lung and elaboration of a combined clinicopathologic and molecular scoring system to predict clinical responsiveness to EGFR inhibitors. Am J Clin Pathol. 2009; 131:478-489.
41. Rickman OB, Vohra PK, Sanyal B, et al. Analysis of ErbB receptors in pulmonary carcinoid tumors. Clin Cancer Res. 2009; 15:3315-3324.
42. Wislez M, Antoine M, Baudrin L, et al. Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarkerexpression and in the response to gefitinib. Lung Cancer.2010; 68:185-191.
43. Chaft JE, Rekhtman N, Ladanyi M, et al. ALK-rearranged lung cancer: adenosquamous lung cancer masquerading as pure squamous carcinoma. J Thorac Oncol. 2012;7:768-769
44. Mino-Kenudson M, Mark EJ. Reflex testing for epidermal growth factor receptor mutation and anaplastic lymphoma kinase fluorescence in situ hybridization in non-small cell lung cancer. Arch Pathol Lab Med. 2011; 135:655-664.
45. D'Angelo SP, Park B, Azzoli CG, et al. Reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutation: report on initial experience and clinical utility at a single center. J Thorac Cardiovasc Surg. 2011; 141:476-480.
46. Girard N, Deshpande C, Azzoli CG, et al. Use of epidermal growth factor receptor/Kirsten rat sarcoma 2 viral oncogene homolog mutation testing to define clonal relationships among multiple lung adenocarcinomas: comparison with clinical guidelines. Chest. 2010; 137:46-52.
47. Warth A, Macher-Goeppinger S, Muley T, et al. Clonality of multifocal nonsmall cell lung cancer: implications for staging and therapy. Eur Respir J. 2012; 39:1437-1442.
48. Ma ES, Cheng PN, Wong CL, et al. Synchronous primary lung cancer and epidermal growth factor receptor mutation. Ann Thorac Surg. 2010; 90:e38-e39.
49. Takamochi K, Oh S, Matsuoka J, et al. Clonality status of multifocal lung adenocarcinomas based on the mutation patterns of EGFR and K-ras. Lung Cancer. 2012; 75:313-320.
50. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012; 366:883-892.
51. Yatabe Y, Matsuo K, Mitsudomi T. Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. J Clin Oncol. 2011; 29:2972-2977.

52. Camidge DR, Kono SA, Flacco A, et al. Optimizing the detection of lung cancer subjects harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res. 2010; 16:5581-5590.
53. Da Cunha Santos G, Saieg MA, Geddie W, et al. EGFR gene status in cytological samples of nonsmall cell lung carcinoma: controversies and opportunities. Cancer Cytopathol. 2011; 119:80-91.
54. Malapelle U, Bellevicine C, Zeppa P, et al. Cytology-based gene mutation tests to predict response to anti-epidermal growth factor receptor therapy: a review. Diagn Cytopathol. 2011; 39:703-710.
55. Rekhtman N, Brandt SM, Sigel CS, et al. Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing. J Thorac Oncol. 2011; 6:451-458.
56. Aisner DL, Deshpande C, Baloch Z, et al. Evaluation of EGFR mutation status in cytology specimens: an institutional experience . Diagn Cytopathol.
57. Betz BL, Roh MH, Weigelin HC, et al. The application of molecular diagnostic studies interrogating EGFR and KRAS mutations to stained cytologic smears of lung carcinoma. Am J Clin Pathol. 2011; 136:564-571.
58. Malapelle U, de Rosa N, Rocco D, et al. EGFR and KRAS mutations detection on lung cancer liquid-based cytology: a pilot study. J Clin Pathol. 2012; 65:87-91.
59. Killian JK, Walker RL, Suuriniemi M, et al. Archival fine needle aspiration cytopathology (FNAC) samples: untapped resource for clinical molecular profiling. JMol Diagn.2010; 12:739-745.
60. Billah S, Stewart J, Staerkel G, et al. EGFR and KRAS mutations in lung carcinoma: molecular testing by using cytology specimens. Cancer Cytopathol. 2011; 119:111-117.
61. Terry J, Leung S, Laskin J, et al. Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples. Am J Surg Pathol. 2010; 34:1805-1811.